ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib

Plain-language summary

This study examines whether the levels of ELR+CXCL cytokines can predict resistance to Sunitinib treatment in patients with metastatic kidney cancer. It was open to patients with metastatic renal cell carcinoma treated with Sunitinib after kidney surgery. It was conducted as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Centre Antoine Lacassagne

Intervention

ELR+CXCL cytokines levels are of sunitinib response

Start date

6/2/2016

Estimated completion

12/30/2019

Countries

France

Related genes

Locations

• Nice, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* patients with mRCC and treated by sunitinib after radical nephrectomy included in SUVEGIL 8 Clinical Trial (Sponsor : Centre Antoine Lacassagne)

Exclusion Criteria:

* Non applicable